Free shipping on all orders over $ 500


Cat. No. M2167

All AbMole products are for research use only, cannot be used for human consumption.

(+)-JQ1 Structure


Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 53  USD53 In stock
2mg USD 32  USD32 In stock
5mg USD 53  USD53 In stock
10mg USD 69  USD69 In stock
50mg USD 142  USD142 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

(+)-JQ1 is a BET bromodomain inhibitor that acts on BRD4(2) with an IC50 of 33 nM and binds to all bromodomain domains in the BET family, but not to bromodomain domains outside the BET family. JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway, and JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway.way.

Product Citations
Customer Product Validations & Biological Datas
Source Cancer Cell (2016). Figure 8. (+)-JQ1 (Abmole Bioscience, Shanghai, China)
Method Treatment started in 4-week-old mice that were euthanized and analyzed at 8 weeks of age.
Cell Lines
Concentrations 50 mg/kg
Incubation Time
Results Inhibition of BET bromodomain by JQ1, known to downregulate c-MYC levels in vivo (Delmore et al., 2011), significantly reduced dysplatic lesions in 8-week-old URI(WT)(+/KI)hep livers (Figures 8O–8Q), consistent with the role of c-MYC in liver tumor progression (Qu et al., 2014).
Source Oncotarget.(2015) . Figure 6. JQ1 (Abmole Bioscience)
Method in vivo
Cell Lines H1975 and A549 lung adenocarcinoma in xenograft mouse models
Concentrations 25 mg/kg i.p.
Incubation Time 20 days
Results Limited effects of the combination of Debio 1143 and JQ1 treatment on tumor volume were observed in H1975 xenografts treated with 30mg/kg Debio 1143; 25mg/kg JQ1 (maximum %treated/control [%T/C] = 52.7%) (Figure 6A). At these drug concentrations, body weights were reduced early in treatment, indicative of toxicity, but body weights stabilized over time (Figure 6B).
Source Oncotarget.(2015) . Figure 5. JQ1 (Abmole Bioscience)
Method western blot
Cell Lines A549, H1975, H2030 cells
Concentrations 1000 nM
Incubation Time 24 h
Results In H1975, H2030, and A549 cells, JQ1 also moderately reduces cIAP1 levels in H1975, A549, and H2030 cells. Protein levels of cIAP1 are undetectable in the Debio 1143/JQ1 combinations (Figure 5A). cIAP2 and XIAP levels were most completely suppressed following combination treatment with Debio 1143 and JQ1 in H1975 cells. Debio 1143 enhanced TNFα mRNA expression in H2030 cells, but not H1975 or A549 (Figure 5B), and JQ1 did not affect TNFα mRNA expression. these results indicate a functioning ripoptosome is formed in the two cell lines most sensitive to the combination of Debio 1143 and JQ1.
Source Oncotarget.(2015) . Figure 4. JQ1 (Abmole Bioscience)
Method western blot
Cell Lines A549, H1975, H2030 cells
Concentrations 1000 nM
Incubation Time 24 h
Results The combination, but neither single agent, elevated IκBα, an NF-κB inhibitor (Figure 4A). Debio 1143, but not JQ1, induced nuclear localization of p52 in each cell line tested - H1975, A549, and H2030, with no augmentation by the combination (Figure 4B, 4C, and 4D).
Source Oncotarget.(2015) . Figure 3. JQ1 (Abmole Bioscience)
Method growth inhibition assays
Cell Lines A549, H1975, H2030 cells
Concentrations 0~100 µ M
Incubation Time 24 h
Results Debio 1143 was also more effective in combination with the bromodomain inhibitor JQ1. Over a period of 24 hours, Debio 1143 alone induced moderate polyADP ribose polymerase (PARP) cleavage in H1975 and H2030 cells; cleaved PARP levels were greatly enhanced in the presence of JQ1 in H1975 and H2030 cells (Figure 3G).
Source Oncotarget.(2015) . Figure 2. JQ1 (Abmole Bioscience)
Method growth inhibition assays
Cell Lines A549, H1650, H1975, H820, H2030 and H2228 cells
Concentrations 0~10 µ M
Incubation Time 24 h
Results A subset of lung adenocarcinoma cell lines was also sensitive to bromodomain inhibition with both iBET (Figure S2B) and JQ1 (Figure 2D).
Protocol (for reference only)
Cell Experiment
Cell lines MM.1S, RPMI-8226, KMS-20, L-363 Dox40 and AMO-1 cell lines
Preparation method Cell Viability Assays MM cell lines were seeded onto 384-well tissue culture treated plates at a density of 1,000 cells/well in a volume of 50 µL of media. After seeding cells were incubated for 1 hour and during the interim a stock plate of JQ1 was thawed at room temperature in a desiccated box. The addition of JQ1 to the assay plate was done with disposable 384-well pins (V&P Scientific, San Diego, CA) that delivered 100 nL of the drug diluted in DMSO to each well of the plate. After 72 hours of incubation cells were analyzed for cell viability by the addition of CellTiter Glo (Promega, Madison, WI) to the assay plates. After 30 min incubation at 37 oC the signal from the viable cells was analyzed on a Luminoskan luminometer (Labsystems Franklin, MA).
Concentrations 0~1µM
Incubation time 72 h
Animal Experiment
Animal models SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells
Formulation JQ1 in 10% cyclodextrine (Sigma)
Dosages 50 mg/kg daily
Administration intra-peritoneally for 5 days/week, 2 weeks
Chemical Information
Molecular Weight 456.99
Formula C23H25ClN4O2S
CAS Number 1268524-70-4
Solubility (25°C) DMSO 45 mg/mL
Ethanol 45 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month

[1] Li Z, et al. Nucleic Acids Res. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation.

[2] Matzuk MM, et al. Cell. Small-molecule inhibition of BRDT for male contraception.

[3] Delmore JE, et al. Cell. BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

[4] Filippakopoulos P, et al. Nature. Selective inhibition of BET bromodomains.

Related Epigenetic Reader Domain Products

Phoenixin-20 (PNX-20) is a bioactive peptide with hormone-like actions in vertebrates, and can stimulates hypothalamo-pituitary-gonadal hormones and regulate reproductive processes in mammals.

Menin-MLL inhibitor 31

Menin-MLL inhibitor 31 is a potent inhibitor of the menin MLL interaction with an IC50 value of 4.6 nM.


OPN-2853 is a bromodomain protein-4 (BRD4) inhibitor that can be used in studies related to hematologic and lymphatic disorders.


HDAC/JAK/BRD4-IN-1 is a potent HDAC/JAK/BRD4 triple inhibitor.


VYN-201 is a novel pan-BET inhibitor for studies related to idiopathic pulmonary fibrosis.

Abmole Inhibitor Catalog

Keywords: (+)-JQ1, JQ1 supplier, Epigenetic Reader Domain, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.